Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.54 |
| ▸ | LSS | P48449 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27544932 | 0.89 | ITGB3 (0.54) | ITGB3ITGA2B | |
| SCHEMBL6794719 | 0.87 | FFAR4 (0.51) | FFAR4 | |
| SCHEMBL12042021 | 0.83 | NOTUM (0.56) | FFAR4 | |
| SCHEMBL381806 | 0.82 | NOTUM (0.54) | FFAR4 | |
| SCHEMBL2942824 | 0.82 | ITGB3 (0.63) | ITGB3ITGA2BLSSFFAR4 | |
| SCHEMBL7329597 | 0.82 | CHKA (0.47) | ITGB3ITGA2BLSS | |
| Hydrochloric Acid SCHEMBL2948256 | 0.81 | ITGB3 (0.62) | ITGB3ITGA2BLSSFFAR4 | |
| SCHEMBL12042028 | 0.81 | PTGER2 (0.54) | FFAR4 | |
| Hydrochloric Acid SCHEMBL9024111 | 0.80 | ITGB3 (0.56) | ITGB3ITGA2B | |
| SCHEMBL7790326 | 0.80 | ITGB3 (0.55) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | ITGB3 4278/4885ITGA2B 2807/4885LSS 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.